Developing a comprehensive community-based bispecific antibody operations program for safe step-up dosing and ongoing management
NCODA Oncology and Hematology Meeting Abstracts · 28.10.2026 · 2 (2)
DOI: 10.67209/vrpz9526 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 28.10.2026. Verfasst von Debra Shapert und 3 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Background
Bispecific antibodies have transformed the treatment landscape for patients with relapsed and refractory hematologic malignancies. Despite demonstrated efficacy, widespread adoption in community oncology practices has been limited by the risk of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infection, and the extensive monitoring required during step-up dosing. Historically, many patients require referral to tertiary academic centers for treatment initiation, creating barriers to access and continuity of care. Maryland Oncology Hematology (MOH) developed a standardized operational program to safely administer bispecific antibody therapy in the community setting while maintaining clinical monitoring, multidisciplinary coordination, and patient safety standards.
Objectives
Describe the key operational, clinical, educational, and multidisciplinary components of a community-based bispecific antibody program that support safe step-up dosing, toxicity monitoring, caregiver engagement, adverse event management, and implementation across oncology practice settings. Significance: A comprehensive bispecific antibody operations program was developed across designated community sites utilizing a multidisciplinary team model that included physicians, advanced practice providers, pharmacists, nurses, clinical managers, practice administrators, educators, and a dedicated Bispecific Champion. Key program elements included patient selection criteria, caregiver requirements, Risk Evaluation and Mitigation Strategy (REMS) coordination, authorization support, pharmacy preparation, toxicity management workflows, and standardized communication pathways. The program incorporated initiation checklists, monitoring tools, symptom journals, wallet cards, caregiver agreements, and educational resources to support patients and staff throughout treatment. Collaborative relationships with community hospitals and emergency departments were established to facilitate timely recognition, communication, and management of treatment-related toxicities, ensuring seamless transitions of care across settings.
Intervention
To safely transition bispecific therapy into the community setting, MOH established standardized processes for patient evaluation, treatment readiness, and post-treatment monitoring. Ideal outpatient candidates were evaluated for performance status, organ function, infection risk, tumor burden, caregiver availability, transportation considerations, and proximity to the treatment center. Step-up dosing workflows included multidisciplinary review, pretreatment laboratory and imaging assessment, QuantiFERON- tuberculosis (TB) testing, pharmacy verification, tocilizumab availability, CRS and ICANS monitoring protocols, and coordinated follow-up visits. Patient and caregiver education focused on symptom recognition, home monitoring of temperature, blood pressure, oxygen saturation, emergency response instructions, medication adherence, and infection prevention measures. The program further incorporated infectious prophylaxis guidance, immunoglobulin monitoring, and escalation pathways for toxicity management or hospital admission when clinically indicated. Adaptability: The framework was intentionally designed for scalability and replication across community oncology practices. Core components include a dedicated bispecific champion role, multidisciplinary coordination, standardized competency training, structured patient-selection criteria, caregiver engagement, toxicity-monitoring tools, pharmacy readiness processes, and transition workflows between academic and community settings. The model supports both outpatient step-up dosing and long-term maintenance administration and may be adapted to accommodate future bispecific therapies and other immune effector cell treatments.
Conclusion
This program demonstrates that community oncology practices can safely implement bispecific antibody therapy through structured planning, comprehensive education, multidisciplinary collaboration, and standardized operational processes. By moving step-up dosing closer to patients’ homes, the program expands access to innovative therapies while maintaining robust safety oversight. Key success factors included standardized workflows, caregiver involvement, proactive toxicity monitoring, infection prevention strategies, and strong coordination across clinical and operational teams. This framework provides a practical roadmap for other community oncology organizations seeking to develop or expand bispecific antibody services. Funding: Not applicable
Zitieren
APA
Shapert, D., Chambers, R., Rauschenberg, E., & Yarbro, L. (2026). Developing a comprehensive community-based bispecific antibody operations program for safe step-up dosing and ongoing management. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/vrpz9526
Vancouver
Shapert D, Chambers R, Rauschenberg E, Yarbro L. Developing a comprehensive community-based bispecific antibody operations program for safe step-up dosing and ongoing management. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/vrpz9526
BibTeX
@article{Shapert2026,
author = {Shapert, Debra and Chambers, Rylie and Rauschenberg, Elizabeth and Yarbro, Laura},
title = {Developing a comprehensive community-based bispecific antibody operations program for safe step-up dosing and ongoing management},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/vrpz9526}
}
EUVIMED